TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24306767

Group type: EXPERIMENTAL
Intervention: Pedometer (Yamax LS2000)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Accelerometer (ActiGraph GT1M/GT3X+)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Both instruments (Pedometer and Accelerometer)
Number of subjects: 122
Study: 23301476

Group type: EXPERIMENTAL
Intervention: Auricular therapy based on the pattern/syndrome differentiation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional auricular point sticking therapy
Number of subjects: 200
Study: 20938590

Group type: EXPERIMENTAL
Intervention: Cow's milk introduced before four months of life
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding for shorter than six months
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding for longer than six months
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Dietary interventions during the first year of life
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Wheezing prevalence
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Asthma prevalence
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Atopy prevalence
Number of subjects: 354
Study: 19077401

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Apomorphine
Number of subjects: 0
Study: 17154776

Group type: EXPERIMENTAL
Intervention: Responses made via word-labeled buttons in the reverse Stroop task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Responses made via color-labeled buttons in the reverse Stroop task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Data from the 4 experiments
Number of subjects: 0
Study: 14551489

Group type: EXPERIMENTAL
Intervention: Dexamethasone therapy for 4 days
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 123
Study: 11064970

Group type: EXPERIMENTAL
Intervention: Continuous passive motion from 0 degrees to 50 degrees and increased as tolerated (Group II)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Continuous passive motion from 70 degrees to 110 degrees (Group III)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No continuous passive motion (Group I)
Number of subjects: 120
Study: 8698446

Group type: EXPERIMENTAL
Intervention: Low-calorie diet (1.9 MJ/d) for 2 weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard diet (6.3 to 8.4 MJ/d) for 4 weeks
Number of subjects: 51
Study: 1450707

Group type: EXPERIMENTAL
Intervention: Interferon (IFN)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 6399463

Group type: EXPERIMENTAL
Intervention: Thermal biofeedback
Number of subjects: 42

Group type: COMPARATOR
Intervention: Abbreviated progressive relaxation
Number of subjects: 42
Study: 29391379

Group type: EXPERIMENTAL
Intervention: Pit-crew device training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard mechanical chest compression device training
Number of subjects: 60
Study: 24700342

Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV) pretreatment for 4 weeks
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV) pretreatment
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no RBV pretreatment)
Number of subjects: 54
Study: 24351147

Group type: EXPERIMENTAL
Intervention: Superelastic nickel-titanium wire
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Multistranded steel wire
Number of subjects: 36

Group type: COMPARATOR
Intervention: Stainless steel wire
Number of subjects: 36
Study: 19713248

Group type: EXPERIMENTAL
Intervention: CAPOX (oxaliplatin 65 mg/m2 i.v. days 1 and 8 and capecitabine 1000 mg/m2 orally b.i.d. days 1-14; q21d)
Number of subjects: 94

Group type: COMPARATOR
Intervention: CAPIRI (irinotecan 80 mg/m2 i.v. days 1 and 8 and capecitabine 1000 mg/m2 orally b.i.d. days 1-14; q21d)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: CAPOX
Number of subjects: 94

Group type: COMPARATOR
Intervention: CAPIRI
Number of subjects: 94
Study: 18724827

Group type: EXPERIMENTAL
Intervention: Myofascial techniques (suboccipital muscle technique, compression of fourth intracranial ventricle, deep cervical fascia technique)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Myofascial techniques
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (resting position)
Number of subjects: 41
Study: 16622803

Group type: EXPERIMENTAL
Intervention: Preincubation of oocytes in follicular fluid for 3 hours after oocyte retrieval
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control oocytes preincubated in normal IVF culture medium
Number of subjects: 0
Study: 12670840

Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate (STS) 0.125 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate (STS) 1.25 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate (STS) 12.5 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate (STS) 125 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate (STS) 1,250 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no STS)
Number of subjects: 10
Study: 10611148

Group type: EXPERIMENTAL
Intervention: 40 mg oral baclofen
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9360033

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises combined with electrical stimulation of pelvic floor (six sessions).
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no treatment).
Number of subjects: 80
Study: 1326584

Group type: EXPERIMENTAL
Intervention: Detection of varicella-zoster virus (VZV) DNA using PCR in oropharyngeal epithelium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Detection of varicella-zoster virus (VZV) DNA using PCR in peripheral blood leukocytes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCR detection of VZV DNA in oropharynx and blood
Number of subjects: 0
Study: 3895210

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 30862500

Group type: EXPERIMENTAL
Intervention: Netarsudil ophthalmic solution 0.02% QD (PM)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Timolol ophthalmic solution 0.5% BID
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Netarsudil QD
Number of subjects: 372

Group type: COMPARATOR
Intervention: Timolol BID
Number of subjects: 372
Study: 28807071

Group type: EXPERIMENTAL
Intervention: Modified BVM with external handle
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard BVM
Number of subjects: 70
Study: 23552589

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1ug/kg administered intravenously over 10 minutes before intubation (group D)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline administered (group C)
Number of subjects: 60
Study: 20708715

Group type: EXPERIMENTAL
Intervention: Family‐Based Behavioral Group Intervention
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Parent‐Only Behavioral Group Intervention
Number of subjects: 240

Group type: COMPARATOR
Intervention: Education Control Condition
Number of subjects: 240
Study: 19787151

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg daily)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 16782924

Group type: EXPERIMENTAL
Intervention: RT‐PCR positive patients (n = 620)
Number of subjects: 1446

Group type: EXPERIMENTAL
Intervention: Detection of more than one RT‐PCR marker in peripheral blood (PBMC) from 820 patients
Number of subjects: 1446

Group type: COMPARATOR
Intervention: RT‐PCR analysis on sentinel lymph nodes (SLNs) and PBMCs
Number of subjects: 1446
Study: 15579735

Group type: EXPERIMENTAL
Intervention: 30 mg octreotide long-acting repeatable (LAR) every 4 wk for 16 wk
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 30 mg octreotide LAR
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (LAR and placebo)
Number of subjects: 50
Study: 11463593

Group type: EXPERIMENTAL
Intervention: Low tidal volume (VT) mechanical ventilation strategy (6 ml/kg)
Number of subjects: 902
Study: 9534750

Group type: EXPERIMENTAL
Intervention: Systemic interferon alpha 2b (IFN‐alpha)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Diagnostic phase serum IL‐2
Number of subjects: 92
Study: 7712001

Group type: EXPERIMENTAL
Intervention: Total Quality Management (TQM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deming adherents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eclectic choices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality improvement techniques
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Top management support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinician support for quality initiatives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total Quality Management (TQM) maturity
Number of subjects: 0
Study: 2853047

Group type: EXPERIMENTAL
Intervention: Rice bran (17.1 g/d)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Wheat bran (15.0 g/d)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no supplement)
Number of subjects: 8
Study: 30269534

Group type: EXPERIMENTAL
Intervention: Online individualised intervention comprising e-learning and decision support e-tools
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Training for care home staff
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: E-learning and e-tools
Number of subjects: 27
Study: 29389474

Group type: EXPERIMENTAL
Intervention: 500 mg rosemary twice daily for one month
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 26821664

Group type: EXPERIMENTAL
Intervention: 6×1 hour practical course with systematic feedback (27 students)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Regular clerkship activities only (21 students)
Number of subjects: 48
Study: 24385519

Group type: EXPERIMENTAL
Intervention: Interactive web-based training program
Number of subjects: 317

Group type: COMPARATOR
Intervention: Existing flat-text e-learning program
Number of subjects: 317
Study: 23025690

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU/dose, given twice daily for 3 days)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 21130361

Group type: EXPERIMENTAL
Intervention: Electrical Acupuncture (EA)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Manual Acupuncture (MA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 50
Study: 18438562

Group type: EXPERIMENTAL
Intervention: Syntac with pressure application before light-curing
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Scotchbond Multi-Purpose with pressure application before light-curing
Number of subjects: 120

Group type: COMPARATOR
Intervention: Syntac without pressure application
Number of subjects: 120

Group type: COMPARATOR
Intervention: Scotchbond Multi-Purpose without pressure application
Number of subjects: 120
Study: 16391299

Group type: EXPERIMENTAL
Intervention: Palifermin (60 microg/kg/d)
Number of subjects: 212
Study: 14552407

Group type: EXPERIMENTAL
Intervention: Parent training intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 0
Study: 10999790

Group type: EXPERIMENTAL
Intervention: 40% carbohydrate diet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 60% carbohydrate diet
Number of subjects: 12
Study: 8625660

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (bud), 1,600 micrograms/d
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide, 1,600 micrograms/d, plus oral prednisolone, 5 micrograms/d (bud + pred)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo (plac)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 58
Study: 1428609

Group type: EXPERIMENTAL
Intervention: HTR polymer implant
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control site (surgically debrided without implant)
Number of subjects: 15
Study: 6307772

Group type: EXPERIMENTAL
Intervention: 200 mg ranitidine twice daily
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine twice daily
Number of subjects: 82
Study: 31601493

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with paclitaxel and carboplatin
Number of subjects: 193

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 193
Study: 28770631

Group type: EXPERIMENTAL
Intervention: Broad-based female empowerment curriculum
Number of subjects: 801

Group type: COMPARATOR
Intervention: Dose-matched science and technology female leadership curriculum
Number of subjects: 801
Study: 26603297

Group type: EXPERIMENTAL
Intervention: Carboplatin (CBDCA, area under the curve = 5) plus pemetrexed (PEM, 500 mg/m²) followed by maintenance pemetrexed (PEM)
Number of subjects: 34
Study: 24676290

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol
Number of subjects: 200

Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both polyethylene glycol and lactulose
Number of subjects: 200
Study: 20633419

Group type: EXPERIMENTAL
Intervention: High-frequency (20 Hz) deep transcranial magnetic stimulation (DTMS) over the prefrontal cortex
Number of subjects: 65

Group type: COMPARATOR
Intervention: Low stimulation intensity DTMS
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: High-intensity DTMS
Number of subjects: 65

Group type: COMPARATOR
Intervention: Low-intensity DTMS
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: DTMS treatment
Number of subjects: 65
Study: 14766684

Group type: EXPERIMENTAL
Intervention: 300 mL clear liquid two hours before surgery
Number of subjects: 126

Group type: COMPARATOR
Intervention: Fasting (no fluid intake)
Number of subjects: 126
Study: 11308062

Group type: EXPERIMENTAL
Intervention: Self-report methods for assessing disability in mobility
Number of subjects: 186

Group type: COMPARATOR
Intervention: Observational method for assessing disability in mobility
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Self-report methods and observational method
Number of subjects: 186
Study: 9692616

Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) therapy for 8 months
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ketanserin treatment for 14 days
Number of subjects: 15

Group type: COMPARATOR
Intervention: Healthy controls and untreated hemodialysis patients
Number of subjects: 15
Study: 7940423

Group type: EXPERIMENTAL
Intervention: Brasfield chest radiograph score
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: NIH chest radiograph score
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: RCH chest radiograph score
Number of subjects: 62
Study: 3078903

Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 200
Study: 11772800

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg before surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Rofecoxib 50 mg after surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31353040

Group type: EXPERIMENTAL
Intervention: Healthy lifestyle behavioral intervention over 3 years
Number of subjects: 605
Study: 29846189

Group type: EXPERIMENTAL
Intervention: Self-reported moderate-to-vigorous-intensity physical activity (MVPA)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Accelerometer-derived MVPA
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Self-regulation (socio-ecological correlate)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Neighborhood aesthetics (socio-ecological correlate)
Number of subjects: 200
Study: 28074750

Group type: EXPERIMENTAL
Intervention: Consultant pharmacist services with academic detailing, medication monitoring system alerts, and structured recommendations for ADE management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 0
Study: 24742498

Group type: EXPERIMENTAL
Intervention: FDC AZI/AML 20/5 mg
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: FDC AZI/AML 20/2.5 mg
Number of subjects: 603

Group type: COMPARATOR
Intervention: AZI 20 mg
Number of subjects: 603

Group type: COMPARATOR
Intervention: AML 5 mg
Number of subjects: 603

Group type: COMPARATOR
Intervention: AML 2.5 mg
Number of subjects: 603
Study: 21614479

Group type: EXPERIMENTAL
Intervention: SRP + NDL at 1 W
Number of subjects: 20

Group type: COMPARATOR
Intervention: SRP
Number of subjects: 20
Study: 19580461

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg per week of risedronate
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 1 mg/kg per week of risedronate
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 2 mg/kg per week of risedronate
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: risedronate (all doses)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 1 or 2 mg/kg per week of risedronate
Number of subjects: 53
Study: 19091088

Group type: EXPERIMENTAL
Intervention: modified Constraint-Induced Movement Therapy (modified CIMT) for 3 weeks
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: EMG-triggered Neuro-Muscular Stimulation (EMG-NMS) for 3 weeks
Number of subjects: 180

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 180
Study: 15777325

Group type: EXPERIMENTAL
Intervention: Progressively loaded implants
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventionally loaded implants
Number of subjects: 20
Study: 12501879

Group type: EXPERIMENTAL
Intervention: Cefditoren 200 mg BID
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: Cefditoren 400 mg BID
Number of subjects: 802

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate 875/125 mg BID
Number of subjects: 802
Study: 10710759

Group type: EXPERIMENTAL
Intervention: KR-withdrawal early in practice
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: KR-withdrawal later in practice
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: KR-withdrawal
Number of subjects: 120
Study: 8551535

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate and Lactobacillus acidophilus
Number of subjects: 27

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate only
Number of subjects: 27
Study: 1775610

Group type: EXPERIMENTAL
Intervention: Unilateral-nondominant ECT (UND)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bilateral ECT (BL)
Number of subjects: 0
Study: 7068295

Group type: EXPERIMENTAL
Intervention: Cycling at 3500 m ASL
Number of subjects: 3
Study: 31374304

Group type: EXPERIMENTAL
Intervention: Ingenol mebutate (IngMeb) 0.027%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study: 31061111

Group type: EXPERIMENTAL
Intervention: Active superior cluneal nerve block
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo block
Number of subjects: 20
Study: 29087167

Group type: EXPERIMENTAL
Intervention: Proactive outreach cessation intervention
Number of subjects: 2406
Study: 27250120

Group type: EXPERIMENTAL
Intervention: DHA emulsion (60 mg/kg/day)
Number of subjects: 1244

Group type: COMPARATOR
Intervention: Control emulsion without DHA
Number of subjects: 1244
Study: 24378629

Group type: EXPERIMENTAL
Intervention: SpineCor brace
Number of subjects: 38

Group type: COMPARATOR
Intervention: Rigid brace
Number of subjects: 38
Study: 21927836

Group type: EXPERIMENTAL
Intervention: LCE 125 mg after LCE 150 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: LCE 100 mg
Number of subjects: 19
Study: 19506174

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate, high-vegetable protein diet (26% of total calories, 31% from gluten, soy, nuts, fruits, vegetables, and cereals, 43% vegetable oil)
Number of subjects: 47

Group type: COMPARATOR
Intervention: High-carbohydrate lacto-ovo vegetarian diet (58% carbohydrate, 16% protein, 25% fat)
Number of subjects: 47
Study: 17452165

Group type: EXPERIMENTAL
Intervention: Exercise oscillatory breathing (EOB)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: VE/VCO2 slope (threshold, < 36.2 or >= 36.2)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: EOB and VE/VCO2 slope combination
Number of subjects: 288
Study: 14991240

Group type: EXPERIMENTAL
Intervention: Partial volume correction (PVC) with global mean normalization
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Partial volume correction (PVC) with cerebellar normalization
Number of subjects: 122

Group type: COMPARATOR
Intervention: No PVC (control group)
Number of subjects: 122
Study: 12568481

Group type: EXPERIMENTAL
Intervention: Immediate therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 0
Study: 9524826

Group type: EXPERIMENTAL
Intervention: Sulbactam/cefoperazone (2 g/4 g every 12 hours)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Imipenem (500 mg every 6 hours)
Number of subjects: 203
Study: 8580951

Group type: EXPERIMENTAL
Intervention: Stair-climbing ergometry at 75% of predicted VO2max for 22 minutes
Number of subjects: 0
Study: 2504834

Group type: EXPERIMENTAL
Intervention: Roxithromycin (RU) at a daily dosage of 300 mg
Number of subjects: 209

Group type: COMPARATOR
Intervention: Josamycin (JM) at a daily dosage of 1200 mg
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Roxithromycin (RU)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Josamycin (JM)
Number of subjects: 209
Study: 1060748

Group type: COMPARATOR
Intervention: Chlorhexidine (positive control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brushing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (no specific agent mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylaxis group (no calculus at start)
Number of subjects: 0
Study: 30080982

Group type: EXPERIMENTAL
Intervention: Fear appeal messages with high threat and high efficacy
Number of subjects: 488

Group type: COMPARATOR
Intervention: Fear appeal messages with varying levels of threat and efficacy
Number of subjects: 488

Group type: COMPARATOR
Intervention: Fear appeal messages across traditional and social media
Number of subjects: 488
Study: 30169183

Group type: EXPERIMENTAL
Intervention: Appointment management intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Current care (control)
Number of subjects: 120